Techgenyz

How to Recover Corrupted Database After MySQL Workbench Export Failed

MySQL Workbench export failed? Learn how to fix common export errors, troubleshoot permissions and version issues, and ...

Using dbx in Practice: The Reality and Startup Procedure of a 25MB Lightweight DB Client

DB clients tend to be a chaotic mix of tools that vary slightly from team to team. Mac users have TablePlus, Windows users have HeidiSQL, and checking on Linux servers is done by typing directly into ...
note

Why using UUIDs as primary keys is slow: A practical performance comparison of INSERTs with AUTO_INCREMENT, UUIDv4, and UUIDv7 in MySQL

When you use a UUID as a primary key for reasons such as "wanting to assign IDs in a distributed environment" or "not wanting to expose sequential numbers in URLs," INSERT operations become noticeably ...
in Bestia

How Much Is MySQL’s Market Value Really Worth in 2024?

MySQL’s name is synonymous with database reliability, but its financial underpinnings—how much it’s worth, who profits from it, and why its valuation matters—remain obscured behind layers of corporate ...
Forbes

Generate Biomedicines IPO Turns Heads

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...
Reuters

Generate Biomedicines shares fall in weak Nasdaq debut for drug developer

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...
MedCity News

Generate Biomedicines’ IPO Brings In $400M for Pivotal Tests of Severe Asthma Drug

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...
FierceBiotech

Behind Generate's 'feverish' race to raise $400M IPO while window remains open

Generate:Biomedicines has earmarked $300 million of its IPO funds to complete a pair of phase 3 asthma trials for its anti-TSLP antibody GB-0895. (Fabrice Cabaud/Stock/Getty Images Plus) ...
Bloomberg

Flagship-Backed Generate Biomedicines Raises $400 Million in IPO

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...
Reuters

Flagship-backed Generate Biomedicines eyes $2.2 billion valuation in US IPO

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...
Seeking Alpha

Generate Biomedicines Begins IPO Push With Major Collaboration Deals

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...